|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.28 USD | -3.11% |
|
-13.42% | +27.30% |
| 06-29 | Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Index | CI |
| 06-29 | Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell Midcap Growth Benchmark | CI |
| Market Cap | 2.87B 2.51B 2.32B 2.14B 4.03B 277B 4.12B 27.71B 10.9B 136B 10.8B 10.56B 467B | P/E 2026 * |
-6.47x | P/E 2027 * | -38.1x |
|---|---|---|---|---|---|
| Enterprise Value | 2.4B 2.09B 1.93B 1.78B 3.36B 231B 3.43B 23.11B 9.09B 113B 9B 8.81B 389B | EV / Sales 2026 * |
3.23x | EV / Sales 2027 * | 2.4x |
| Free-Float |
96.26% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ultragenyx Pharmaceutical Inc.
| 1 day | -3.11% | ||
| 1 week | -13.42% | ||
| Current month | -12.31% | ||
| 1 month | +6.71% | ||
| 3 months | +18.02% | ||
| 6 months | +30.19% | ||
| Current year | +27.30% |
| 1 week | 28.9 |  | 33.58 |
| 1 month | 27.49 | | 36.57 |
| Current year | 18.29 | | 36.57 |
| 1 year | 18.29 | | 39.89 |
| 3 years | 18.29 | | 60.37 |
| 5 years | 18.29 | | 104.38 |
| 10 years | 18.29 | | 179.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emil Kakkis
CEO | Chief Executive Officer | 65 | 2010-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 49 | 2023-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | 53 | 2023-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 64 | 2017-04-05 |
Emil Kakkis
BRD | Director/Board Member | 65 | 2010-04-21 |
Daniel Welch
CHM | Chairman | 68 | 2015-06-17 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/1/26 | Sell | Chief Financial Officer | -4,698 | 0.0048% | ||
| 6/15/26 | Sell | Director | -2,000 | 0.0020% | ||
| 6/15/26 | Sell | General Counsel | -1,899 | 0.0019% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.11% | -13.42% | +11.29% | -33.77% | 2.87B | |
| -0.06% | -9.13% | +22.34% | -83.85% | 1.82B | |
| +0.53% | -0.32% | -11.32% | -14.70% | 320M | |
| -0.42% | -4.05% | -47.22% | - | 50.98M | |
| Average | -0.76% | -6.73% | -6.23% | -44.11% | 1.27B | |
| Weighted average by Cap. | -1.76% | -10.96% | +13.24% | -50.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 741M 648M 598M 551M 1.04B 71.41B 1.06B 7.15B 2.81B 34.97B 2.78B 2.72B 120B | 985M 861M 794M 732M 1.38B 94.86B 1.41B 9.49B 3.73B 46.46B 3.7B 3.62B 160B |
| Net income | -475M -415M -383M -353M -666M -45.78B -681M -4.58B -1.8B -22.42B -1.79B -1.75B -77.19B | -87.97M -76.88M -70.94M -65.39M -123M -8.47B -126M -848M -334M -4.15B -330M -323M -14.28B |
| Net Debt | -478M -418M -385M -355M -669M -46.01B -684M -4.61B -1.81B -22.53B -1.79B -1.75B -77.57B | -508M -444M -410M -378M -712M -48.96B -728M -4.9B -1.93B -23.98B -1.91B -1.87B -82.55B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-17 | US$29.28 | -3.11% | 1,500,530 |
| 26-07-16 | US$30.22 | -4.70% | 1,829,572 |
| 26-07-15 | US$31.71 | -1.00% | 1,012,610 |
| 26-07-14 | US$32.03 | -3.58% | 1,078,132 |
| 26-07-13 | US$33.22 | -1.77% | 1,394,276 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RARE Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
